Skip to content

Exploration and practice of the three-level whole-process management model for thyroid nodule and differentiated thyroid carcinoma

Exploration and practice of the three-level whole-process management model for thyroid nodule and differentiated thyroid carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036777
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodule and differentiated thyroid carcinoma

Interventions

case series:Nil

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The age range is 18~70 years old 2. Known thyroid nodules or thyroid cancer risk factors Risk factors for thyroid cancer (2012 Chinese Guidelines for the Diagnosis and Treatment of thyroid nodule and differentiated thyroid cancer): (1) History of head and neck radiation exposure or fallout exposure in childhood; (2) History of systemic radiotherapy; (3) Previous or family history of DTC, medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2), familial polyposis, and certain thyroid cancer syndromes (such as Cowden syndrome, Carney syndrome, Werner syndrome, Gardner syndrome, etc.); (4) Men; (5) Nodules grow rapidly; (6) Accompanied by persistent hoarseness and difficulty in pronunciation, and can exclude lesions on the vocal cords (inflammation, polyps, etc.); (7) With difficulty in swallowing or breathing; (8) nodules irregular shape, with the surrounding tissue adhesion fixed; (9) With pathologic enlargement of cervical lymph nodes. 3. Volunteer to participate in this study to provide complete general information.

Exclusion criteria

Exclusion criteria: 1. Patients with other autoimmune diseases, tumors and other chronic diseases; 2. Women during pregnancy; 3. People with mental disorders; 4. Perennial bedridden disabled persons; 5. Those who cannot complete screening or intervention for other reasons.

Design outcomes

Primary

MeasureTime frame
Thyroid Stimulating Hormone;Thyroid nodule size;

Countries

China

Contacts

Public ContactHuanbai Xu

Shanghai General Hospital

huanbaixu@126.com+86 15800622510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026